Modafinil 200 mg Tablets
ERIMOD-200 is a modafinil tablet that contains Modafinil 200 mg USP. ERIMOD-200 is marketed by Eridanus Healthcare. Modafinil is a eugeroic which comes under Schedule X drug. Modafinil is a drug that increases wakefulness and sustained alertness without causing peripheral stimulant effects or dependency behaviour like typical amphetamines used for treating EDS (excessive daytime sleepiness). Modafinil is used for the treatment of EDS caused by various diseases such as narcolepsy, obstructive sleep apnoea, and SWSD.
ERIMOD-200 tablets are available from Eridanus Healthcare Neuro/psychiatry PCD Pharma Franchise in a blister pack of 10×10.
Uses and Indications of Modafinil 200 mg Tablets
Indications for which ERIMOD-200 is recommended by neurologists and sleep specialists include:
- Narcolepsy – a neurological disorder of sleep characterised by excessive daytime sleepiness and sleep attacks
- Obstructive Sleep Apnoea (OSA) – persistent excessive daytime sleepiness after CPAP treatment
- Shift Work Sleep Disorder (SWSD) – sleepiness and attention-deficit in workers on night shift and rotating shifts
- Adjunct treatment of fatigue in MS (multiple sclerosis) – as per neurologist’s advice
- Attention-deficit and cognitive fatigue in some neuropsychiatric disorders – as advised by specialists
- Adjunct treatment of treatment-resistant depression fatigue – as adjunct to antidepressant therapy as prescribed by psychiatrist
How Modafinil 200 mg Tablets Work?
The exact mechanism of how Modafinil promotes wakefulness remains to be fully elucidated; however, the drug works by selectively inhibiting the dopamine reuptake transporter (DAT) to promote an increase in extracellular dopamine – mainly in the wake-promoting areas of the hypothalamus and the nucleus accumbens. Different from amphetamine drugs, Modafinil does not result in a general release of monoamines and does not impact noradrenaline and serotonin reuptake in the same way; this explains why Modafinil is less likely to produce abuse or dependency and has a lesser number of cardiovascular side effects. The use of Modafinil also results in indirect activation of the orexin (hypocretin) neurons in the lateral hypothalamus – the area of the brain responsible for promoting wakefulness.
PCD Pharma Franchise for Modafinil 200 mg Tablets – Eridanus Healthcare
Eridanus Healthcare is a speciality Neuro/Psychiatry pharmaceutical company providing a unique line of prescription medicines in Anti-Depressants, Anti-Anxiety, CNS & Neurological Disorders, Psychiatry, Neurological Pain, and allied treatment areas. Pharma professionals, medical representatives, and distributors from all over India are welcome to collaborate with Eridanus Healthcare for the PCD Pharma Franchise and Monopoly Distribution rights of ERIMOD-200 and our full spectrum of Neuro/Psychiatry medicines.
Why Partner with Eridanus Healthcare for Neuro PCD Pharma Franchise?
- Exclusive Monopoly-based PCD Pharma Franchise rights for ERIMOD-200 and our entire Eridanus Neuro/Psychiatry portfolio in your district or state
- Unique portfolio of Neuro/Psychiatry medications including Anti-Depressants, Anti-Anxiety, Anti-Psychotics, CNS drugs, Neurological Pain, and Nutrition & Wellness range
- Highly profitable net rates along with attractive profit margins and MRP pricing
- GMP-certified manufacture from WHO-approved manufacturing units
- Free promotional materials – visual aids, MR bags, sample kits, reminder cards, and product literature
- On-time processing of orders and assured pan-India distribution network
- Experienced franchise team for onboarding and support
- Expanding market of Neuro/Psychiatry treatments in India
Note: The above content contains only informational text and does not claim anything. Therefore, must inform your doctor before taking this medication.